<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Maternal adaptations to pregnancy: Hematologic changes
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Maternal adaptations to pregnancy: Hematologic changes
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Maternal adaptations to pregnancy: Hematologic changes
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kenneth A Bauer, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Charles J Lockwood, MD, MHCM
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Lawrence LK Leung, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Vanessa A Barss, MD, FACOG
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jennifer S Tirnauer, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Apr 08, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H376279017">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pregnancy is characterized by profound changes in almost every organ system to accommodate the growing and developing fetoplacental unit. The major hematologic changes include expanded plasma volume, physiologic anemia, mild neutrophilia in some individuals, and a mild prothrombotic state. The clinician must be able to distinguish these anticipated physiologic changes from those caused by pregnancy-related complications.
        </p>
        <p>
         This topic discusses physiologic changes in blood volume, blood cells, and hemostasis during pregnancy. Cardiovascular and vascular changes associated with pregnancy and hematologic complications of pregnancy are discussed in separate topic reviews:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/443.html" rel="external">
          "Maternal adaptations to pregnancy: Cardiovascular and hemodynamic changes"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/115637.html" rel="external">
          "Anemia in pregnancy"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/90654.html" rel="external">
          "Approach to the adult with unexplained neutropenia"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/6681.html" rel="external">
          "Thrombocytopenia in pregnancy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1430782889">
         <span class="h1">
          OVERVIEW
         </span>
        </p>
        <p class="headingAnchor" id="H401109712">
         <span class="h2">
          Normal hematologic changes in pregnancy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The most significant hematologic changes during pregnancy include the following and are detailed in the table (
         <a class="graphic graphic_table graphicRef89214" href="/z/d/graphic/89214.html" rel="external">
          table 1
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Expanded plasma volume (in excess of the increase in red blood cell mass) and resultant physiologic anemia
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mild neutrophilia
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mild thrombocytopenia
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Increased procoagulant factors and decreased natural anticoagulants
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Diminished fibrinolysis
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1548795187">
         <span class="h2">
          Hematologic changes of concern
         </span>
         <span class="headingEndMark">
          —
         </span>
         The following findings are not consistent with normal, physiologic adaptation to pregnancy and should prompt additional evaluation, and possibly additional interventions. In general, more severe abnormal findings require more prompt consultation by a hematologist.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Nonphysiologic anemia or polycythemia
         </strong>
         , especially when associated with symptoms out of proportion to the stage of pregnancy.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Hemoglobin levels &lt;10 g/dL or &gt;16 g/dL should prompt hematologic evaluation unless the etiology is known or the abnormalities are related to a preexistent chronic condition. (See
         <a class="medical medical_review" href="/z/d/html/115637.html" rel="external">
          "Anemia in pregnancy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4517.html" rel="external">
          "Clinical manifestations and diagnosis of polycythemia vera"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Evidence of iron deficiency
         </strong>
         (eg, iron studies showing reduced iron stores or new microcytosis, which is a late finding of iron deficiency). Iron deficiency is common because the demand for iron is increased in pregnancy (
         <a class="graphic graphic_figure graphicRef116876" href="/z/d/graphic/116876.html" rel="external">
          figure 1
         </a>
         ). However, pregnant patients can have iron deficiency anemia with ferritin levels in the low-normal reference range and approximately one-third of those with iron deficiency do not manifest microcytosis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         While many prenatal vitamins contain iron, the content may be insufficient for treatment of patients with iron deficiency. Oral iron supplements are one option, but are often poorly tolerated because of gastric irritation and/or constipation. Parenteral iron administration should be considered in patients with iron deficiency anemia who do not respond to or cannot tolerate oral iron supplementation. (See
         <a class="medical medical_review" href="/z/d/html/115637.html" rel="external">
          "Anemia in pregnancy", section on 'Management'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Thalassemia
         </strong>
         is another major cause of microcytic anemia. In some cases, it is not diagnosed until pregnancy. (See
         <a class="medical medical_review" href="/z/d/html/115637.html" rel="external">
          "Anemia in pregnancy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4432.html" rel="external">
          "Microcytosis/Microcytic anemia"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Leukocytosis or leukopenia.
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Leukocytosis due to an excess of neutrophils can occur in some individuals during pregnancy in the absence of infection or inflammatory conditions. Findings prompting hematology consultation include a white blood cell (WBC) count &gt;20,000/microL in the absence of labor or infection, or a WBC differential showing immature myeloid or lymphoid forms or a marked excess of lymphocytes.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Leukopenia in association with an absolute neutrophil count &lt;1000/microL that is unexplained also requires hematologic evaluation. (See
         <a class="medical medical_review" href="/z/d/html/8381.html" rel="external">
          "Approach to the patient with neutrophilia"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/90654.html" rel="external">
          "Approach to the adult with unexplained neutropenia"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Severe thrombocytopenia or thrombocytopenia with bleeding
         </strong>
         . Gestational thrombocytopenia with a reduced platelet count (typically, between 80,000 and 149,000/microL) is common during pregnancy. Levels below this level should prompt hematologic consultation. (See
         <a class="medical medical_review" href="/z/d/html/6681.html" rel="external">
          "Thrombocytopenia in pregnancy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Thrombocytosis
         </strong>
         . The new onset of thrombocytosis is unusual during pregnancy, and platelet counts &gt;500,000/microL should prompt hematologic evaluation. Platelet counts &gt;1,000,000/microL require urgent evaluation. (See
         <a class="medical medical_review" href="/z/d/html/6682.html" rel="external">
          "Approach to the patient with thrombocytosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4491.html" rel="external">
          "Clinical manifestations, pathogenesis, and diagnosis of essential thrombocythemia"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2885433145">
         <span class="h1">
          HEMATOLOGIC CHANGES OF SPECIFIC BLOOD COMPONENTS DURING PREGNANCY
         </span>
        </p>
        <p class="headingAnchor" id="H1549271045">
         <span class="h2">
          Plasma volume
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Plasma volume increases by 10 to 15 percent at 6 to 12 weeks of gestation, expands rapidly until 30 to 34 weeks, and then plateaus or decreases slightly through term (
         <a class="graphic graphic_figure graphicRef61948" href="/z/d/graphic/61948.html" rel="external">
          figure 2
         </a>
         ) [
         <a href="#rid1">
          1-3
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The total gain at term averages 1100 to 1600 mL and results in a total plasma volume of 4700 to 5200 mL, which is 30 to 50 percent above that in nonpregnant women [
         <a href="#rid1">
          1,4,5
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Total plasma volume expansion is accompanied by retention of 900 to 1000 mEq of sodium and 6 to 8 L of water, which is distributed among the fetus, amniotic fluid, and extracellular and intracellular spaces [
         <a href="#rid6">
          6,7
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         The expanded plasma volume is thought to meet the increased metabolic demands of the uterus and placenta, facilitate delivery of nutrients to the developing fetus and removal of waste, protect against the effects of impaired venous return when the mother is supine or standing, and protect the mother from excessive blood loss during delivery [
         <a href="#rid8">
          8
         </a>
         ]. No specific measures are available to expand the plasma volume in pregnancy and no evidence that the expansion of plasma volume would reverse or prevent associated poor pregnancy outcomes associated with low plasma volume. In theory, increasing dietary protein could improve colloid oncotic pressure (COP), which would shift extravascular fluid to the intravascular space. For dehydrated patients, increasing maternal hydration may also act synergistically with a higher COP to improve intravascular volume.
        </p>
        <p>
         The rise in plasma volume during pregnancy is probably a response to an underfilled vascular system caused by systemic vasodilatation and the rise in vascular capacitance. During pregnancy, plasma renin activity tends to be increased and atrial natriuretic peptide levels are slightly reduced [
         <a href="#rid9">
          9,10
         </a>
         ]. The converse picture (low plasma renin activity and elevated natriuretic peptide, suggestive of a vascular response to expanded plasma volume) are not seen. The hypothesis that vascular changes precede expansion of the plasma volume is also supported by the observation that increasing sodium intake does not lead to further volume expansion [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2012487277">
         <span class="h2">
          Red blood cells
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Red blood cell (RBC) mass begins to increase at 8 to 10 weeks of gestation, steadily rises, and reaches levels 20 to 30 percent higher than in nonpregnant females by the end of pregnancy [
         <a href="#rid4">
          4,11-14
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The increased RBC mass is accompanied by a slight increase in the mean corpuscular volume (MCV) (
         <a class="graphic graphic_table graphicRef89214" href="/z/d/graphic/89214.html" rel="external">
          table 1
         </a>
         ) in healthy pregnant people [
         <a href="#rid15">
          15
         </a>
         ]. However, as noted above, the increase in RBC mass is smaller than the increase in plasma volume, which contributes to the physiologic anemia of pregnancy. (See
         <a class="local">
          'Dilutional or physiologic anemia'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The increase in RBC mass requires sufficient iron, folate, and vitamin B12; thus, individuals with deficiencies of iron or these vitamins will have blunted increases in RBC mass and are likely to develop more severe anemia. As an example, in a series of 69 pregnant patients not receiving iron supplements, the RBC mass was estimated to increase by 15 to 20 percent rather than the normal 20 to 30 percent and the MCV decreased to an average value of 80 to 84 fL in the third trimester [
         <a href="#rid16">
          16,17
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Iron requirement
         </strong>
         – In a typical singleton gestation, maternal iron requirements average close to 1000 mg over the course of pregnancy (
         <a class="graphic graphic_figure graphicRef116876" href="/z/d/graphic/116876.html" rel="external">
          figure 1
         </a>
         ): approximately 300 mg for the fetus and placenta and approximately 500 mg, if available, for the expansion of the maternal RBC mass [
         <a href="#rid8">
          8
         </a>
         ]. An additional 200 mg is shed through the gut, urine, and skin.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Since most patients do not have adequate iron stores to meet the demands of pregnancy, iron is commonly prescribed as part of a prenatal multivitamin or as a separate supplement. In general, pregnant patients taking iron supplements have a mean hemoglobin concentration that is 1 g/dL greater than that of those not taking supplements.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Reference ranges for iron indices in pregnancy are listed in the table (
         <a class="graphic graphic_table graphicRef115338" href="/z/d/graphic/115338.html" rel="external">
          table 2
         </a>
         ). Recommended iron intake and treatment of iron deficiency in pregnancy are presented in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/115637.html" rel="external">
          "Anemia in pregnancy", section on 'Prevention of iron deficiency'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Folate requirement
         </strong>
         – The increased folate demand for RBC creation is more than met by the higher daily intake (400 to 800 mcg) already recommended for prevention of neural tube defects [
         <a href="#rid18">
          18,19
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/423.html" rel="external">
          "Preconception and prenatal folic acid supplementation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/453.html" rel="external">
          "Nutrition in pregnancy: Dietary requirements and supplements"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         The major mediator of increased RBC mass is an increase in erythropoietin, which stimulates RBC production [
         <a href="#rid8">
          8
         </a>
         ]. Erythropoietin levels increase by 50 percent in normal pregnancies and vary according to the presence of pregnancy complications [
         <a href="#rid20">
          20
         </a>
         ]. RBC lifespan is also slightly decreased during normal pregnancy [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p>
         The increased RBC mass partially supports the higher metabolic requirement for oxygen during pregnancy [
         <a href="#rid22">
          22
         </a>
         ]. In addition, levels of RBC 2,3 bisphosphoglycerate (2,3-BPG, also called 2,3-diphosphoglycerate [2,3-DPG]) remain elevated during pregnancy, which leads to a decrease in oxygen affinity (ie, a shift of the hemoglobin-oxygen dissociation curve to the right) (
         <a class="graphic graphic_figure graphicRef81216" href="/z/d/graphic/81216.html" rel="external">
          figure 3
         </a>
         ) [
         <a href="#rid23">
          23
         </a>
         ]. This lower oxygen affinity, combined with low pCO
         <sub>
          2
         </sub>
         of the maternal blood due to increased minute ventilation, facilitates transport of oxygen across the placenta and to the fetal RBCs, which have greater oxygen affinity due to fetal hemoglobin. The function of fetal hemoglobin is reviewed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/90749.html" rel="external">
          "Fetal hemoglobin (Hb F) in health and disease", section on 'Biology of Hb F'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H929618389">
         <span class="h3">
          Dilutional or physiologic anemia
         </span>
         <span class="headingEndMark">
          —
         </span>
         In normal pregnancies, greater expansion of plasma volume relative to the increase in RBC mass is associated with a modest decrease in hemoglobin concentration, which is referred to as physiologic or dilutional anemia of pregnancy. The greatest disproportion between the rates at which plasma and RBCs are added to the maternal circulation occurs during the late second to early third trimester; thus, the lowest hemoglobin concentration is typically measured at 28 to 36 weeks [
         <a href="#rid17">
          17
         </a>
         ]. Nearer to term, hemoglobin concentration increases due to cessation of plasma expansion and continuing increase in RBC mass (
         <a class="graphic graphic_figure graphicRef61948" href="/z/d/graphic/61948.html" rel="external">
          figure 2
         </a>
         ).
        </p>
        <p>
         Determining a precise laboratory value that defines anemia in pregnancy is not straightforward because of normal pregnancy-associated changes in plasma volume and RBC mass. The Centers for Disease Control and Prevention, National Academy of Medicine, and the World Health Organization thresholds for diagnosing anemia in pregnancy are:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Centers for Disease Control and Prevention – Anemia in pregnancy is defined as a hemoglobin level &lt;11 g/dL (approximately equivalent to a hematocrit &lt;33 percent) in the first and third trimesters and &lt;10.5 g/dL (hematocrit &lt;32 percent) in the second trimester [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The World Health Organization – Anemia in pregnancy is defined as a hemoglobin level &lt;110 g/L (&lt;11 g/dL) or a hematocrit &lt;6.83 mmol/L (&lt;33 percent) [
         <a href="#rid25">
          25
         </a>
         ]. Severe anemia is defined as a hemoglobin level &lt;70 g/L (&lt;7 g/dL). Very severe anemia is defined as hemoglobin &lt;40 g/L (&lt;4 g/dL).
        </p>
        <p>
        </p>
        <p>
         However, a hemoglobin as low as 10 g/dL can be attributed to physiologic anemia after pathologic causes of anemia have been excluded since a wide variety of factors can affect the normal level of hemoglobin in a specific individual. (See
         <a class="medical medical_review" href="/z/d/html/115637.html" rel="external">
          "Anemia in pregnancy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H898939564">
         <span class="h2">
          White blood cells
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pregnancy affects WBCs in different ways at different stages of pregnancy. Importantly, an increase in WBC associated with fever, a large number of immature WBC forms, or any blasts in the peripheral blood are not normal and should be evaluated promptly. (See
         <a class="medical medical_review" href="/z/d/html/8381.html" rel="external">
          "Approach to the patient with neutrophilia"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The neutrophil count begins to increase in the second month of pregnancy and plateaus in the second or third trimester, at which time WBC counts range from 9000 to 15,000 cells/microL [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mean WBC counts in laboring patients were 10,000 to 16,000 cells/microL in two reports, with an upper level as high as 29,000 cells/microL [
         <a href="#rid27">
          27,28
         </a>
         ]. The mean count increased linearly with the duration of elapsed labor [
         <a href="#rid28">
          28
         </a>
         ]. As noted above, we advise hematologic evaluation of pregnant patients with a WBC count greater than 20,000/microL in the absence of labor or infection or a WBC differential showing immature myeloid or lymphoid forms or a marked excess of lymphocytes. (See
         <a class="local">
          'Hematologic changes of concern'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         An increase in the percent of bands as pregnancy advances has been reported [
         <a href="#rid29">
          29-31
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A small number of myelocytes or metamyelocytes may be seen in the peripheral circulation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Dohle bodies (blue-staining cytoplasmic inclusions in granulocytes) may be seen. (See
         <a class="medical medical_review" href="/z/d/html/4435.html" rel="external">
          "Evaluation of the peripheral blood smear", section on 'Neutrophil series'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4435.html" rel="external">
          "Evaluation of the peripheral blood smear", section on 'Granulation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The absolute lymphocyte count and the relative numbers of T and B lymphocytes do not change [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The monocyte count is generally stable.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The basophil count may decrease slightly.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The eosinophil count may increase slightly.
        </p>
        <p>
        </p>
        <p>
         Alterations in the function of the immune system during pregnancy are presented in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/3966.html" rel="external">
          "Immunology of the maternal-fetal interface"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3053335344">
         <span class="h2">
          Platelets
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The platelet count declines as pregnancy progresses, but generally remains in the normal nonpregnant range (approximately 150,000 to 450,000/microL) [
         <a href="#rid33">
          33
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the vast majority of uncomplicated pregnancies, the platelet count remains ≥100,000/microL and returns to the prepregnancy baseline level by several weeks postpartum.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The most common cause of a decline in platelet count is a normal physiologic response referred to as gestational thrombocytopenia (GT; also called incidental thrombocytopenia of pregnancy). GT is a diagnosis of exclusion and may recur in subsequent pregnancies. We generally do not evaluate patients with a mild decrease in platelet count during pregnancy as long as they are asymptomatic and their platelet count is ≥100,000/microL. (See
         <a class="medical medical_review" href="/z/d/html/6681.html" rel="external">
          "Thrombocytopenia in pregnancy", section on 'Gestational thrombocytopenia (GT)'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Moderate to severe thrombocytopenia (platelet count &lt;100,000/microL) is rare in pregnancy, but when it occurs, it may be a medical emergency. Possible causes include immune thrombocytopenia, preeclampsia with severe features, sepsis with disseminated intravascular coagulation; HELLP syndrome (syndrome of hemolysis, elevated liver enzymes, and low platelets); thrombotic thrombocytopenic purpura; antiphospholipid syndrome; and drug-induced thrombocytopenia. Evaluation and management of moderate to severe thrombocytopenia in pregnancy are discussed in detail separately; early involvement of the consulting hematologist is advised. (See
         <a class="medical medical_review" href="/z/d/html/6681.html" rel="external">
          "Thrombocytopenia in pregnancy", section on 'Symptomatic, platelets &lt;100,000/microL, bleeding, thrombosis, or other major findings'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1298717641">
         <span class="h2">
          Coagulation and fibrinolysis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The hemostatic system ensures appropriate clot formation via complex interactions between coagulation factors (
         <a class="graphic graphic_figure graphicRef90873" href="/z/d/graphic/90873.html" rel="external">
          figure 4
         </a>
         ), platelets, and the vascular endothelium. The fibrinolytic system prevents excessive coagulation via removal of fibrin and clot dissolution (
         <a class="graphic graphic_table graphicRef70156" href="/z/d/graphic/70156.html" rel="external">
          table 3
         </a>
         and
         <a class="graphic graphic_figure graphicRef81428" href="/z/d/graphic/81428.html" rel="external">
          figure 5
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/1371.html" rel="external">
          "Overview of hemostasis"
         </a>
         .)
        </p>
        <p>
         Normal pregnancy is a prothrombotic state [
         <a href="#rid34">
          34-44
         </a>
         ]. The shift in the balance between the hemostatic and fibrinolytic systems serves to prevent excessive hemorrhage during placental separation. Compared with nonpregnant females, pregnant people have a marked increase in some coagulation factors, reduced fibrinolysis, and increased platelet reactivity. As a consequence, there is increased risk for thromboembolic complications. While these changes increase the risk of thrombosis, they are not themselves an indication for intervention.
        </p>
        <p>
         Laboratory tests of coagulation are not routinely performed (or required) during pregnancy. The following changes occur in circulating levels of coagulation factors, inhibitors, and fibrinolytic markers (
         <a class="graphic graphic_table graphicRef115338" href="/z/d/graphic/115338.html" rel="external">
          table 2
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Increased procoagulant factors
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Procoagulant factors fibrinogen, factors II, VII, VIII, X, and XII increase by 20 to 200 percent [
         <a href="#rid44">
          44
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The prohemostatic von Willebrand factor (VWF) can increase substantially from baseline during pregnancy. Studies have reported that VWF increases by two- to fourfold during pregnancy, peaks within 24 hours postpartum, and returns to baseline by one month postpartum [
         <a href="#rid45">
          45
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Reduced anticoagulant factors
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The anticoagulant protein S decreases physiologically in nearly all pregnant people, such that they appear protein S deficient based on reference ranges established for normal populations (measured as total protein S, free protein S, and protein S activity) [
         <a href="#rid46">
          46
         </a>
         ]. If a patient develops venous thromboembolism (VTE) during pregnancy and concern for an inherited thrombophilia exists, testing of protein S levels should be deferred until after delivery. However, most pregnant patients with VTE do not require thrombophilia testing.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Several studies have found that antithrombin (AT) levels are unchanged or slightly increased antepartum. One study, however, reported that AT decreases by approximately 20 percent [
         <a href="#rid47">
          47
         </a>
         ]. Immediately after birth, AT levels fall to 30 percent below baseline level, with a nadir reached approximately 12 hours after delivery, likely due to consumption. AT levels return to baseline by 72 hours postpartum. The relatively large and rapid changes in the postpartum levels of AT have not been consistently documented, likely in part because both the reduction and resolution are swift [
         <a href="#rid40">
          40,44,48-52
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Reduced fibrinolysis
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Activity of fibrinolytic inhibitors increases, including thrombin activatable fibrinolytic inhibitor, plasminogen activator inhibitor-1 (PAI-1), and PAI-2 [
         <a href="#rid53">
          53
         </a>
         ]. PAI-1 levels increase markedly since it is partly derived from the placenta and decidua.
        </p>
        <p>
        </p>
        <p>
         There is evidence of ongoing coagulation, including increased thrombin cleavage products, increased fibrin D-dimer, increased fibrin monomers, and increased fibrinopeptides A and B [
         <a href="#rid54">
          54-61
         </a>
         ]. Components of the fibrinolytic system also increase, including plasminogen and tissue type plasminogen activator [
         <a href="#rid62">
          62
         </a>
         ].
        </p>
        <p>
         Factor XIII levels normally decrease by 20 to 30 percent during the second and third trimesters [
         <a href="#rid63">
          63
         </a>
         ]. The mechanism is unclear; hypotheses include a potential role for factor XIII in anchoring the cytotrophoblast of the placenta to the uterine lining. Other anticoagulant and procoagulant proteins (eg, protein C, factor V, and factor IX) remain mostly unchanged [
         <a href="#rid44">
          44,64
         </a>
         ].
        </p>
        <p>
         The activated partial thromboplastin time remains in the normal range during pregnancy but decreases (shortens) slightly near term, and the prothrombin time may decrease (shorten) [
         <a href="#rid48">
          48
         </a>
         ].
        </p>
        <p>
         It is worth noting that certain tests, such as D-dimer, have diminished diagnostic accuracy in evaluating the likelihood of VTE due to the increase that can occur during normal pregnancy (ie, higher cutoff levels are required below which the result has a high negative predictive value for acute VTE). (See
         <a class="medical medical_review" href="/z/d/html/89374.html" rel="external">
          "Pulmonary embolism in pregnancy: Clinical presentation and diagnosis", section on 'Oxygenation measures'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2004774641">
         <span class="h1">
          POSTPARTUM RESOLUTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pregnancy-related hematologic changes return to baseline by six to eight weeks after delivery [
         <a href="#rid65">
          65
         </a>
         ]. Within this range, the rate and pattern of resolution of pregnancy-related changes of specific hematological parameters vary.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Plasma volume
         </strong>
         – Plasma volume decreases immediately after delivery, then increases again two to five days later, possibly because of a rise in aldosterone secretion. Plasma volume then decreases; it is still elevated by 10 to 15 percent above nonpregnant levels at three weeks postpartum but is usually at normal nonpregnant levels at six weeks postpartum.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          White blood cells
         </strong>
         – The white blood cell count falls to the normal nonpregnant range by the sixth day postpartum.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Physiologic anemia
         </strong>
         – Physiologic anemia should resolve by six weeks postpartum since plasma volume has returned to normal by that time. In a study of 9000 patients with asymptomatic postpartum anemia (average hematocrit 30.8 percent) at an urban hospital, the average hematocrit level approximately three weeks after discharge was 38.8 percent [
         <a href="#rid66">
          66
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Platelets
         </strong>
         – For most pregnant individuals, the platelet count remains within the normal range during pregnancy and does not change postpartum. For those with gestational thrombocytopenia, mild thrombocytopenia begins to resolve soon after delivery and is no longer present at three to four weeks postpartum.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Coagulation and fibrinolysis
         </strong>
         – Postpartum normalization of coagulation parameters and return to baseline thromboembolic risk generally occur by six to eight weeks after delivery [
         <a href="#rid65">
          65
         </a>
         ]. For patients who require thrombophilia testing, we suggest delaying testing until three months following delivery and after lactation has been completed [
         <a href="#rid44">
          44
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Failure of an abnormal laboratory test to normalize within these time frames indicates that further evaluation is needed.
        </p>
        <p class="headingAnchor" id="H3659316925">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/111043.html" rel="external">
          "Society guideline links: Anemia in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2527745833">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Major hematologic changes
         </strong>
         – The major hematologic changes during pregnancy include expanded plasma volume, physiologic anemia, mild neutrophilia in some individuals, and a prothrombotic state that does not require intervention (
         <a class="graphic graphic_table graphicRef89214" href="/z/d/graphic/89214.html" rel="external">
          table 1
         </a>
         ). More severe changes may warrant additional testing and/or interventions. (See
         <a class="local">
          'Overview'
         </a>
         above and
         <a class="local">
          'Hematologic changes of concern'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Physiologic (dilutional) anemia
         </strong>
         – Physiologic (dilutional) anemia occurs because plasma volume increases to a greater extent than red blood cell mass. (See
         <a class="local">
          'Plasma volume'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The Centers for Disease Control and Prevention have defined physiologic anemia as hemoglobin levels &lt;11 g/dL in the first and third trimesters and &lt;10.5 g/dL in the second trimester. More severe anemia is most commonly due to iron deficiency. (See
         <a class="local">
          'Dilutional or physiologic anemia'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/115637.html" rel="external">
          "Anemia in pregnancy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          White blood cell count
         </strong>
         – The white blood cell (WBC) count begins to increase in the second month of pregnancy and plateaus in the second or third trimester (typical WBC range: 9000 to 15,000 cells/microL). This results in mild neutrophilia in some individuals. There is no change in the absolute lymphocyte count. (See
         <a class="local">
          'White blood cells'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Platelet count
         </strong>
         – The platelet count may be slightly lower in pregnancy (eg, below the normal range or below the individual's baseline), but most pregnant people have normal platelet counts (
         <a class="graphic graphic_table graphicRef115338" href="/z/d/graphic/115338.html" rel="external">
          table 2
         </a>
         ). The most common cause of mild thrombocytopenia is gestational thrombocytopenia (typical platelet count range, 100,000 to 149,000/microL), which does not require any intervention and resolves after delivery. More severe thrombocytopenia typically requires further evaluation and treatment. (See
         <a class="local">
          'Platelets'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/6681.html" rel="external">
          "Thrombocytopenia in pregnancy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Coagulation
         </strong>
         – Pregnancy is a prothrombotic state due to changes in several procoagulant and anticoagulant factors (
         <a class="graphic graphic_table graphicRef115338" href="/z/d/graphic/115338.html" rel="external">
          table 2
         </a>
         ). Most pregnant people do not require coagulation testing, but if testing is performed, the prothrombin time (PT) and activated partial thromboplastin time (aPTT) are typically normal or slightly decreased (shortened). Certain tests of coagulation such as the D-dimer have diminished accuracy in predicting the likelihood of VTE during pregnancy. (See
         <a class="local">
          'Coagulation and fibrinolysis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Postpartum resolution
         </strong>
         – Pregnancy-related hematologic changes generally return to baseline by six to eight weeks after delivery. Failure to do so indicates the need for additional evaluation. (See
         <a class="local">
          'Postpartum resolution'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Lund CJ, Donovan JC. Blood volume during pregnancy. Significance of plasma and red cell volumes. Am J Obstet Gynecol 1967; 98:394.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bernstein IM, Ziegler W, Badger GJ. Plasma volume expansion in early pregnancy. Obstet Gynecol 2001; 97:669.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Whittaker PG, Lind T. The intravascular mass of albumin during human pregnancy: a serial study in normal and diabetic women. Br J Obstet Gynaecol 1993; 100:587.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pritchard JA. Changes in the blood volume during pregnancy. Anesthesiology 1965; 26:393.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Haas S, Ghossein-Doha C, van Kuijk SM, et al. Physiological adaptation of maternal plasma volume during pregnancy: a systematic review and meta-analysis. Ultrasound Obstet Gynecol 2017; 49:177.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lindheimer MD, Katz AI. Sodium and diuretics in pregnancy. N Engl J Med 1973; 288:891.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brown MA, Whitworth JA. The kidney in hypertensive pregnancies--victim and villain. Am J Kidney Dis 1992; 20:427.
          </a>
         </li>
         <li class="breakAll">
          Maternal physiology. In: Williams Obstetrics, 24th ed, Cunningham FG, Leveno KJ, Bloom SL, et al (Eds), McGraw-Hill Education, 2014. p.55.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schrier RW. Pathogenesis of sodium and water retention in high-output and low-output cardiac failure, nephrotic syndrome, cirrhosis, and pregnancy (2). N Engl J Med 1988; 319:1127.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nadel AS, Ballermann BJ, Anderson S, Brenner BM. Interrelationships among atrial peptides, renin, and blood volume in pregnant rats. Am J Physiol 1988; 254:R793.
          </a>
         </li>
         <li class="breakAll">
          Metcalfe J, Stock MK, Barron DH. Maternal physiology during gestation. In: The Physiology of Reproduction, Knobil K, Ewing L (Eds), Raven Press, New York 1988. p.2145.
         </li>
         <li>
          <a class="nounderline abstract_t">
           McLennan CE. Plasma volume late in pregnancy. Am J Obstet Gynecol 1950; 59:662.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Campbell DM, MacGillivray I. Comparison of maternal response in first and second pregnancies in relation to baby weight. J Obstet Gynaecol Br Commonw 1972; 79:684.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ueland K. Maternal cardiovascular dynamics. VII. Intrapartum blood volume changes. Am J Obstet Gynecol 1976; 126:671.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haram K, Nilsen ST, Ulvik RJ. Iron supplementation in pregnancy--evidence and controversies. Acta Obstet Gynecol Scand 2001; 80:683.
          </a>
         </li>
         <li class="breakAll">
          Hytten FE, Lind T. Indices of cardiovascular function. In: Diagnostic Indices in Pregnancy, Hytten FE, Lind T (Eds), Documenta Geigy, Basel 1973.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Whittaker PG, Macphail S, Lind T. Serial hematologic changes and pregnancy outcome. Obstet Gynecol 1996; 88:33.
          </a>
         </li>
         <li class="breakAll">
          https://ods.od.nih.gov/factsheets/Folate-HealthProfessional/ (Accessed on October 03, 2017).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cheschier N, ACOG Committee on Practice Bulletins-Obstetrics. ACOG practice bulletin. Neural tube defects. Number 44, July 2003. (Replaces committee opinion number 252, March 2001). Int J Gynaecol Obstet 2003; 83:123.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harstad TW, Mason RA, Cox SM. Serum erythropoietin quantitation in pregnancy using an enzyme-linked immunoassay. Am J Perinatol 1992; 9:233.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lurie S, Mamet Y. Red blood cell survival and kinetics during pregnancy. Eur J Obstet Gynecol Reprod Biol 2000; 93:185.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Milman N, Graudal N, Nielsen OJ, Agger AO. Serum erythropoietin during normal pregnancy: relationship to hemoglobin and iron status markers and impact of iron supplementation in a longitudinal, placebo-controlled study on 118 women. Int J Hematol 1997; 66:159.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bille-Brahe NE, Rørth M. Red cell 2.3-diphosphoglycerate in pregnancy. Acta Obstet Gynecol Scand 1979; 58:19.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Centers for Disease Control (CDC). CDC criteria for anemia in children and childbearing-aged women. MMWR Morb Mortal Wkly Rep 1989; 38:400.
          </a>
         </li>
         <li class="breakAll">
          World Health Organization. Iron deficiency anaemia: Assessment, prevention, and control. A guide for programme managers. http://www.who.int/nutrition/publications/en/ida_assessment_prevention_control.pdf (Accessed on September 06, 2011).
         </li>
         <li>
          <a class="nounderline abstract_t">
           KUVIN SF, BRECHER G. Differential neutrophil counts in pregnancy. N Engl J Med 1962; 266:877.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Molberg P, Johnson C, Brown TS. Leukocytosis in labor: what are its implications? Fam Pract Res J 1994; 14:229.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Acker DB, Johnson MP, Sachs BP, Friedman EA. The leukocyte count in labor. Am J Obstet Gynecol 1985; 153:737.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Siegel I, Gleicher N. Peripheral white blood cell alterations in early labor. Diagn Gynecol Obstet 1981; 3:123.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fernández-Suárez A, Pascual VT, Gimenez MT, Hernández JF. Immature granulocyte detection by the SE-9000 haematology analyser during pregnancy. Clin Lab Haematol 2003; 25:347.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pramanik SS, Pramanik T, Mondal SC, Chanda R. Number, maturity and phagocytic activity of neutrophils in the three trimesters of pregnancy. East Mediterr Health J 2007; 13:862.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kühnert M, Strohmeier R, Stegmüller M, Halberstadt E. Changes in lymphocyte subsets during normal pregnancy. Eur J Obstet Gynecol Reprod Biol 1998; 76:147.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reese JA, Peck JD, Deschamps DR, et al. Platelet Counts during Pregnancy. N Engl J Med 2018; 379:32.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paidas MJ, Ku DH, Arkel YS. Screening and management of inherited thrombophilias in the setting of adverse pregnancy outcome. Clin Perinatol 2004; 31:783.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Greer IA. Epidemiology, risk factors and prophylaxis of venous thrombo-embolism in obstetrics and gynaecology. Baillieres Clin Obstet Gynaecol 1997; 11:403.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Greer IA. Thrombosis in pregnancy: maternal and fetal issues. Lancet 1999; 353:1258.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lindqvist P, Dahlbäck B, Marŝál K. Thrombotic risk during pregnancy: a population study. Obstet Gynecol 1999; 94:595.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Andersen BS, Steffensen FH, Sørensen HT, et al. The cumulative incidence of venous thromboembolism during pregnancy and puerperium--an 11 year Danish population-based study of 63,300 pregnancies. Acta Obstet Gynecol Scand 1998; 77:170.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hellgren M, Blombäck M. Studies on blood coagulation and fibrinolysis in pregnancy, during delivery and in the puerperium. I. Normal condition. Gynecol Obstet Invest 1981; 12:141.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stirling Y, Woolf L, North WR, et al. Haemostasis in normal pregnancy. Thromb Haemost 1984; 52:176.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Comp PC, Thurnau GR, Welsh J, Esmon CT. Functional and immunologic protein S levels are decreased during pregnancy. Blood 1986; 68:881.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cumming AM, Tait RC, Fildes S, et al. Development of resistance to activated protein C during pregnancy. Br J Haematol 1995; 90:725.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bremme KA. Haemostatic changes in pregnancy. Best Pract Res Clin Haematol 2003; 16:153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hellgren M. Hemostasis during normal pregnancy and puerperium. Semin Thromb Hemost 2003; 29:125.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sood SL, James AH, Ragni MV, et al. A prospective study of von Willebrand factor levels and bleeding in pregnant women with type 1 von Willebrand disease. Haemophilia 2016; 22:e562.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paidas MJ, Ku DH, Lee MJ, et al. Protein Z, protein S levels are lower in patients with thrombophilia and subsequent pregnancy complications. J Thromb Haemost 2005; 3:497.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           James AH, Rhee E, Thames B, Philipp CS. Characterization of antithrombin levels in pregnancy. Thromb Res 2014; 134:648.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cerneca F, Ricci G, Simeone R, et al. Coagulation and fibrinolysis changes in normal pregnancy. Increased levels of procoagulants and reduced levels of inhibitors during pregnancy induce a hypercoagulable state, combined with a reactive fibrinolysis. Eur J Obstet Gynecol Reprod Biol 1997; 73:31.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dahlman T, Hellgren M, Blombäck M. Changes in blood coagulation and fibrinolysis in the normal puerperium. Gynecol Obstet Invest 1985; 20:37.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gerbasi FR, Bottoms S, Farag A, Mammen E. Increased intravascular coagulation associated with pregnancy. Obstet Gynecol 1990; 75:385.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sánchez-Luceros A, Meschengieser SS, Marchese C, et al. Factor VIII and von Willebrand factor changes during normal pregnancy and puerperium. Blood Coagul Fibrinolysis 2003; 14:647.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wickström K, Edelstam G, Löwbeer CH, et al. Reference intervals for plasma levels of fibronectin, von Willebrand factor, free protein S and antithrombin during third-trimester pregnancy. Scand J Clin Lab Invest 2004; 64:31.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ku DH, Arkel YS, Paidas MP, Lockwood CJ. Circulating levels of inflammatory cytokines (IL-1 beta and TNF-alpha), resistance to activated protein C, thrombin and fibrin generation in uncomplicated pregnancies. Thromb Haemost 2003; 90:1074.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Francalanci I, Comeglio P, Alessandrello Liotta A, et al. D-dimer plasma levels during normal pregnancy measured by specific ELISA. Int J Clin Lab Res 1997; 27:65.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Senent M, Bellart J, Zuazu-Jausoro I, et al. [Markers of hypercoagulability during pregnancy: thrombin-antithrombin-III complexes and D dimer]. Sangre (Barc) 1991; 36:21.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Wersch JW, Ubachs JM. Blood coagulation and fibrinolysis during normal pregnancy. Eur J Clin Chem Clin Biochem 1991; 29:45.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mercelina-Roumans PE, Ubachs JM, van Wersch JW. Coagulation and fibrinolysis in smoking and nonsmoking pregnant women. Br J Obstet Gynaecol 1996; 103:789.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bremme K, Ostlund E, Almqvist I, et al. Enhanced thrombin generation and fibrinolytic activity in normal pregnancy and the puerperium. Obstet Gynecol 1992; 80:132.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bellart J, Gilabert R, Fontcuberta J, et al. Fibrinolysis changes in normal pregnancy. J Perinat Med 1997; 25:368.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chabloz P, Reber G, Boehlen F, et al. TAFI antigen and D-dimer levels during normal pregnancy and at delivery. Br J Haematol 2001; 115:150.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kline JA, Williams GW, Hernandez-Nino J. D-dimer concentrations in normal pregnancy: new diagnostic thresholds are needed. Clin Chem 2005; 51:825.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bonnar J, McNicol GP, Douglas AS. Fibrinolytic enzyme system and pregnancy. Br Med J 1969; 3:387.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sharief LT, Lawrie AS, Mackie IJ, et al. Changes in factor XIII level during pregnancy. Haemophilia 2014; 20:e144.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clark P, Brennand J, Conkie JA, et al. Activated protein C sensitivity, protein C, protein S and coagulation in normal pregnancy. Thromb Haemost 1998; 79:1166.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saha P, Stott D, Atalla R. Haemostatic changes in the puerperium '6 weeks postpartum' (HIP Study) - implication for maternal thromboembolism. BJOG 2009; 116:1602.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ragsdale AS, Thiele LR, Byrne JJ, et al. Natural history of postpartum hematocrit recovery in an urban, safety-net population. Am J Obstet Gynecol MFM 2022; 4:100541.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 429 Version 39.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5621454" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Blood volume during pregnancy. Significance of plasma and red cell volumes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11339913" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Plasma volume expansion in early pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8334096" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : The intravascular mass of albumin during human pregnancy: a serial study in normal and diabetic women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14313451" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Changes in the blood volume during pregnancy
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28169502" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Physiological adaptation of maternal plasma volume during pregnancy: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4571247" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Sodium and diuretics in pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1442756" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : The kidney in hypertensive pregnancies--victim and villain.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1442756" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : The kidney in hypertensive pregnancies--victim and villain.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3050523" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Pathogenesis of sodium and water retention in high-output and low-output cardiac failure, nephrotic syndrome, cirrhosis, and pregnancy (2)
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2966593" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Interrelationships among atrial peptides, renin, and blood volume in pregnant rats.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2966593" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Interrelationships among atrial peptides, renin, and blood volume in pregnant rats.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15405831" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Plasma volume late in pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5070881" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Comparison of maternal response in first and second pregnancies in relation to baby weight.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/984141" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Maternal cardiovascular dynamics. VII. Intrapartum blood volume changes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11531608" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Iron supplementation in pregnancy--evidence and controversies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11531608" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Iron supplementation in pregnancy--evidence and controversies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8684758" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Serial hematologic changes and pregnancy outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8684758" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Serial hematologic changes and pregnancy outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14626221" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : ACOG practice bulletin. Neural tube defects. Number 44, July 2003. (Replaces committee opinion number 252, March 2001).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1627210" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Serum erythropoietin quantitation in pregnancy using an enzyme-linked immunoassay.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11074141" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Red blood cell survival and kinetics during pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9277046" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Serum erythropoietin during normal pregnancy: relationship to hemoglobin and iron status markers and impact of iron supplementation in a longitudinal, placebo-controlled study on 118 women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/419949" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Red cell 2.3-diphosphoglycerate in pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2542755" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : CDC criteria for anemia in children and childbearing-aged women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2542755" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : CDC criteria for anemia in children and childbearing-aged women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14460983" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Differential neutrophil counts in pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7976474" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Leukocytosis in labor: what are its implications?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4073137" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : The leukocyte count in labor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7261863" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Peripheral white blood cell alterations in early labor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14641137" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Immature granulocyte detection by the SE-9000 haematology analyser during pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17955769" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Number, maturity and phagocytic activity of neutrophils in the three trimesters of pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9481564" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Changes in lymphocyte subsets during normal pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29972751" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Platelet Counts during Pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15519428" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Screening and management of inherited thrombophilias in the setting of adverse pregnancy outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9488783" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Epidemiology, risk factors and prophylaxis of venous thrombo-embolism in obstetrics and gynaecology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10217099" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Thrombosis in pregnancy: maternal and fetal issues.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10511366" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Thrombotic risk during pregnancy: a population study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9512321" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : The cumulative incidence of venous thromboembolism during pregnancy and puerperium--an 11 year Danish population-based study of 63,300 pregnancies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7239349" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Studies on blood coagulation and fibrinolysis in pregnancy, during delivery and in the puerperium. I. Normal condition.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6084322" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Haemostasis in normal pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2944555" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Functional and immunologic protein S levels are decreased during pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7647019" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Development of resistance to activated protein C during pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12763484" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Haemostatic changes in pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12709915" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Hemostasis during normal pregnancy and puerperium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27704648" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : A prospective study of von Willebrand factor levels and bleeding in pregnant women with type 1 von Willebrand disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15748239" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Protein Z, protein S levels are lower in patients with thrombophilia and subsequent pregnancy complications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25087890" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Characterization of antithrombin levels in pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9175686" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Coagulation and fibrinolysis changes in normal pregnancy. Increased levels of procoagulants and reduced levels of inhibitors during pregnancy induce a hypercoagulable state, combined with a reactive fibrinolysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3930349" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Changes in blood coagulation and fibrinolysis in the normal puerperium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2137574" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Increased intravascular coagulation associated with pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14517489" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Factor VIII and von Willebrand factor changes during normal pregnancy and puerperium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15029874" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Reference intervals for plasma levels of fibronectin, von Willebrand factor, free protein S and antithrombin during third-trimester pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14652639" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Circulating levels of inflammatory cytokines (IL-1 beta and TNF-alpha), resistance to activated protein C, thrombin and fibrin generation in uncomplicated pregnancies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9144030" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : D-dimer plasma levels during normal pregnancy measured by specific ELISA.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1853270" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : [Markers of hypercoagulability during pregnancy: thrombin-antithrombin-III complexes and D dimer].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1904779" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Blood coagulation and fibrinolysis during normal pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8760709" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Coagulation and fibrinolysis in smoking and nonsmoking pregnant women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1534880" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Enhanced thrombin generation and fibrinolytic activity in normal pregnancy and the puerperium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9350608" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Fibrinolysis changes in normal pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11722426" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : TAFI antigen and D-dimer levels during normal pregnancy and at delivery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15764641" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : D-dimer concentrations in normal pregnancy: new diagnostic thresholds are needed.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5797779" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Fibrinolytic enzyme system and pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24329777" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Changes in factor XIII level during pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9657443" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Activated protein C sensitivity, protein C, protein S and coagulation in normal pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19681851" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Haemostatic changes in the puerperium '6 weeks postpartum' (HIP Study) - implication for maternal thromboembolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34875414" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Natural history of postpartum hematocrit recovery in an urban, safety-net population.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
